Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations

K Yoshida, Y Yatabe, J Park, S Ogawa, JY Park… - Journal of cancer …, 2010 - Springer
Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non–small-cell lung cancer with epidermal growth factor receptor gene …

A Inoue, T Suzuki, T Fukuhara, M Maemondo… - Journal of Clinical …, 2006 - ascopubs.org
Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …

First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan …

K Tamura, I Okamoto, T Kashii, S Negoro… - British journal of …, 2008 - nature.com
The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …

A phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations

H Asahina, K Yamazaki, I Kinoshita, S Ogura… - Journal of Clinical …, 2006 - ascopubs.org
13014 Background: Activating mutations in exon 18–21 of the epidermal growth factor
receptor (EGFR) gene have been reported to be a predictor of response to gefitinib. We …

Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)

S Morita, T Hirashima, K Hagiwara, T Hida… - Journal of Clinical …, 2008 - ascopubs.org
8101 Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene
are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (EGFR …

[HTML][HTML] Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated …

M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

Q Zhou, XC Zhang, ZH Chen, XL Yin… - Journal of clinical …, 2011 - ascopubs.org
Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …

Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib

SW Han, TY Kim, PG Hwang, S Jeong, J Kim… - Journal of clinical …, 2005 - ascopubs.org
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …